memantine hydrochloride


Also found in: Dictionary.
Related to memantine hydrochloride: donepezil hydrochloride

me·man·tine hydrochloride

(mə-măn′tēn)
n.
A drug used to treat moderate to severe symptoms of Alzheimer's disease, whose action is to inhibit NMDA receptors.
Mentioned in ?
References in periodicals archive ?
Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Memantine Hydrochloride Oral Solution 2 mg/mL, the therapeutic similar to the reference listed drug Namenda Oral Solution, 2 mg/mL of Forest Pharmaceuticals.
It is not known if Memantine Hydrochloride Tablets are safe and effective in children.
With the FDA approval of Upsher-Smith's generic Memantine Hydrochloride Tablets, it is our hope to increase access to a cost-effective alternative to Namenda[sup.
The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution.
FDA has sanctioned the new drug application (NDA) for Namzaric to take care of moderate to severe dementia of the Alzheimer's type in patients stabilised on memantine hydrochloride and donepezil hydrochloride.
Namzaric, a fixed-dose combination of memantine hydrochloride extended-release (ER), an N-methyl D-aspartate receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor (AchEI) has receives approval from FDA.
Namzaric was sanctioned for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
DUBLIN, Ireland, May 18, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that NAMZARIC(TM) (memantine hydrochloride extended-release and donepezil hydrochloride), a once-daily, fixed-dose combination of memantine hydrochloride extended-release (a NMDA receptor antagonist), and donepezil hydrochloride (an acetylcholinesterase inhibitor), is now available to patients and healthcare professionals across the United States.
2014) NAMZARIC (memantine hydrochloride extended-release and donepezil hydrochloride) was approved by the FDA in December 2014 for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
and key International markets, we were pleased to announce the FDA approval of Namzaric, our fixed-dose combination (FDC) of memantine hydrochloride extended-release and donepezil hydrochloride for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on memantine hydrochloride and donepezil hydrochloride.
Food and Drug Administration (FDA) approved the Company's New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.
Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.